Voyager Therapeutics Inc (VYGR) — Titan Protect Analysis

VYGR

Voyager Therapeutics Inc

Healthcare · ·

$3.33

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$218M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.29

Based on estimated future earnings — lower means cheaper

Rev Growth

-59.9%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-52.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$12.00

+260% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neu

https://www.voyagertherapeutics.com

Country: United States Employees: 141 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.315

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0502

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.506

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-35.7%

Historical annualised return based on price data

Max Drawdown

-70.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.26

Moves slightly more than the broader market

52W High

$5.55

40% below the year high

52W Low

$2.83

18% above the year low

Avg Volume

682,714

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.98

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

19.90

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-243.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,167.4%

Profit from core operations before interest and tax

Free Cash Flow

$-80,829,624

Negative — the business is spending more than it generates

Revenue (TTM)

$36M

Total revenue over the last 12 months

Net Income

$-116,637,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$25.00

Target Median

$12.00

Target Low

$8.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go